http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
-
Emergent BioSolutions (EBS) Wins $235.8M Contract to Supply BioThrax to US DoD
-
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
-
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
-
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
-
Emergent BioSolutions (EBS) Receives NYSE Notice Regarding Delayed Form 10-Q Filing
-
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
-
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
-
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
-
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
-
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
-
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
-
Emergent BioSolutions' (EBS) NARCAN Nasal Spray Launches Over the Counter
-
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
-
Emergent BioSolutions (EBS) Announces Strategic Steps to Strengthen Core Business and Financial Position
-
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
-
Emergent BioSolutions (EBS) Awarded 10-Year BARDA Contract Valued at up to $704M
-
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
-
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
-
Emergent BioSolutions (EBS) Receives FDA Approval for CYFENDUS
-
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
-
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
-
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
-
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
-
Emergent BioSolutions Reports Financial Results For First Quarter 2023
-
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
-
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
-
Emergent BioSolutions (EBS) Confirms U.S. FDA Approves Over-the-Counter Designation for NARCAN Nasal Spray
-
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
-
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
-
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
-
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
-
Emergent BioSolutions (EBS) confirms FDA AdComm votes in favor of OTC NARCAN
-
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
-
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
-
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
-
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
-
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
-
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
-
Emergent BioSolutions (EBS) Announces Organizational Changes
-
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
-
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
-
Emergent BioSolutions (EBS) Wins $379.6M Procurement Contract to Supply RSDL to US DoD
-
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
-
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
-
Emergent BioSolutions (EBS) Announces FDA Accepts sNDA for OTC NARCAN
-
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
-
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
-
Emergent BioSolutions (EBS) Announces DoD Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
